Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.
Grant Jones, Felipe Herrmann, Erica Wang
Addictive behaviors reports December 1, 2023 DOI: 10.1016/j.abrep.2023.100513 via PubMed
Summary
AI-generated from the abstractLifetime use of PCP is most strongly linked to hallucinogen dependence or abuse, increasing odds more than sixfold, while LSD, ketamine, and mescaline also raise odds of certain diagnostic criteria. Among 5,252 recent hallucinogen initiates, PCP use was associated with over six times higher odds of hallucinogen dependence or abuse (adjusted odds ratio 6.27), and it increased odds on all three main dependence and abuse criteria. LSD increased odds on two criteria, and ketamine and mescaline each increased odds on one criterion. MDMA, psilocybin, and peyote showed no significant associations. The findings suggest specific hallucinogens differ substantially in their links to disordered use.
Study at a glance
| Characteristics | Cross-sectional survey analysis Longitudinal Peer reviewed |
|---|---|
| Sample size | 5,252 |
| Population | Individuals in the US who initiated hallucinogen use within the past two years |
| Keywords | Hallucinogens Substance abuse Addiction research Drug dependence Psychedelics |
| Citations | 6 |
| Key finding | Lifetime PCP use was associated with over six times higher odds of hallucinogen dependence or abuse, while LSD, ketamine, and mescaline increased odds of some diagnostic criteria. |
Abstract
Hallucinogen dependence and abuse are DSM-IV diagnoses that are associated with significant morbidity, yet the specific hallucinogens that are most strongly linked to dependence and abuse are understudied. We used recent data from the National Survey on Drug Use and Health (2015-2020) and multivariable logistic regression to test the relationships that lifetime use of seven individual hallucinogens (MDMA/ecstasy, PCP, ketamine, psilocybin, LSD, peyote, and mescaline) shares with hallucinogen dependence and abuse among individuals who initiated hallucinogen use within the past two years (N = 5,252). We controlled for various demographic factors (sex, age, race/ethnicity, educational attainment, self-reported engagement in risky behavior, annual household income, marital status) and lifetime use of various substances. Lifetime PCP use was associated with increased odds of hallucinogen dependence or abuse (aOR [95% CI]: 6.27 [1.51, 26.0]). Additionally, PCP increased the odds of three main hallucinogen dependence and abuse criteria measures (aOR [95% CI]: 4.45 [1.11, 17.8], 5.58 [1.42, 22.0], and 7.01 [1.87, 26.3]). LSD conferred increased odds of two criteria (aOR: 2.33 [1.37, 3.98] and 2.53 [1.48, 4.33]), while ketamine and mescaline each conferred increased odds of one criterion (aOR: 2.12 [1.03, 4.39]; 5.39 [1.05, 27.7]). Future longitudinal studies and Bayesian statistical analyses can further assess the relationships between hallucinogens and disordered hallucinogen use.